Stockhead on MSN5h
In big news week Neurizon secures key orphan status for motor neurone drug in EuropeTwas the week before Christmas and the good news was flowing for clinical stage biotech Neurizon Therapeutics (ASX:NUZ), ...
Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Amyotrophic Lateral Sclerosis ...
The Centers for Medicare and Medicaid Services is directing all Medicare Advantage plans to cover Qalsody for treating ...
A new meta-analysis suggests that active exercise may slow functional decline in ALS, while noninvasive brain stimulation ...
SPONSORED GUEST ARTICLE] [SPONSORED GUEST ARTICLE] The big generative AI bang of November 2022 -- OpenAI’s release of ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and ...
Dazucorilant failed to slow disease progression in ALS patients in the DAZALS Phase 2 clinical trial, but may have extended ...
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...
Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback